{
  "success": true,
  "pagesUsed": [
    0,
    1,
    2
  ],
  "modelUsed": "gemini-3-flash-preview",
  "metadata": {
    "studyName": "A Phase 3, Randomized, Open-Label Study Evaluating the Efficacy of Axicabtagene Ciloleucel versus St",
    "titles": [
      {
        "id": "title_1",
        "text": "A Phase 3, Randomized, Open-Label Study Evaluating the Efficacy of Axicabtagene Ciloleucel versus Standard of Care Therapy in Subjects with Relapsed/Refractory Diffuse Large B Cell Lymphoma (ZUMA-7)",
        "type": {
          "code": "Official Study Title",
          "codeSystem": "USDM",
          "decode": "Official Study Title"
        },
        "instanceType": "StudyTitle"
      },
      {
        "id": "title_2",
        "text": "ZUMA-7",
        "type": {
          "code": "Study Acronym",
          "codeSystem": "USDM",
          "decode": "Study Acronym"
        },
        "instanceType": "StudyTitle"
      }
    ],
    "identifiers": [
      {
        "id": "sid_1",
        "text": "KTE-C19-107",
        "scopeId": "org_1",
        "instanceType": "StudyIdentifier",
        "identifierType": {
          "code": "SponsorProtocolNumber",
          "codeSystem": "USDM",
          "decode": "Sponsor Protocol Number"
        }
      },
      {
        "id": "sid_2",
        "text": "016278",
        "scopeId": "org_unknown",
        "instanceType": "StudyIdentifier",
        "identifierType": {
          "code": "IND",
          "codeSystem": "USDM",
          "decode": "FDA IND Number"
        }
      },
      {
        "id": "sid_3",
        "text": "2017-002261-22",
        "scopeId": "org_eudract",
        "instanceType": "StudyIdentifier",
        "identifierType": {
          "code": "EudraCT",
          "codeSystem": "USDM",
          "decode": "EudraCT Number"
        }
      },
      {
        "id": "sid_4",
        "text": "KTE-C19",
        "scopeId": "org_1",
        "instanceType": "StudyIdentifier",
        "identifierType": {
          "code": "SponsorProtocolNumber",
          "codeSystem": "USDM",
          "decode": "Sponsor Protocol Number"
        }
      }
    ],
    "organizations": [
      {
        "id": "org_1",
        "name": "Kite Pharma, Inc.",
        "type": {
          "id": "25d5d739-40d5-4994-9a5d-537957497127",
          "code": "C54086",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Pharmaceutical Company",
          "instanceType": "Code"
        },
        "identifier": "Kite Pharma, Inc.",
        "identifierScheme": "DUNS",
        "instanceType": "Organization"
      },
      {
        "id": "org_2",
        "name": "Gilead Sciences Inc.",
        "type": {
          "id": "3cfbcd56-a9d6-43fc-a0c2-34ec27251ed5",
          "code": "C54086",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Pharmaceutical Company",
          "instanceType": "Code"
        },
        "identifier": "Gilead Sciences Inc.",
        "identifierScheme": "DUNS",
        "instanceType": "Organization"
      },
      {
        "id": "org_3",
        "name": "Data Safety Monitoring Board",
        "type": {
          "id": "bfa469a9-0dec-44d6-8b1d-51b56a9f1380",
          "code": "C25461",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Regulatory Agency",
          "instanceType": "Code"
        },
        "identifier": "Data Safety Monitoring Board",
        "identifierScheme": "DUNS",
        "instanceType": "Organization"
      }
    ],
    "roles": [
      {
        "id": "role_1",
        "name": "Sponsor",
        "code": {
          "code": "Sponsor",
          "codeSystem": "USDM",
          "decode": "Sponsor"
        },
        "organizationIds": [
          "org_1"
        ],
        "instanceType": "StudyRole"
      },
      {
        "id": "role_2",
        "name": "Parent Company",
        "code": {
          "code": "Sponsor",
          "codeSystem": "USDM",
          "decode": "Sponsor"
        },
        "organizationIds": [
          "org_2"
        ],
        "instanceType": "StudyRole"
      },
      {
        "id": "role_3",
        "name": "Safety Oversight",
        "code": {
          "code": "Sponsor",
          "codeSystem": "USDM",
          "decode": "Sponsor"
        },
        "organizationIds": [
          "org_3"
        ],
        "instanceType": "StudyRole"
      }
    ],
    "indications": [
      {
        "id": "ind_1",
        "name": "Relapsed/Refractory Diffuse Large B Cell Lymphoma",
        "isRareDisease": false,
        "instanceType": "Indication",
        "description": "Adult subjects with relapsed/refractory diffuse large B-cell lymphoma (r/r DLBCL) after first-line rituximab and anthracycline-based chemotherapy."
      }
    ],
    "studyPhase": {
      "code": "Phase3",
      "codeSystem": "USDM",
      "decode": "Phase3"
    },
    "studyType": "Interventional"
  },
  "rawResponse": {
    "titles": [
      {
        "id": "title_1",
        "text": "A Phase 3, Randomized, Open-Label Study Evaluating the Efficacy of Axicabtagene Ciloleucel versus Standard of Care Therapy in Subjects with Relapsed/Refractory Diffuse Large B Cell Lymphoma (ZUMA-7)",
        "type": {
          "code": "OfficialStudyTitle",
          "codeSystem": "http://www.cdisc.org/USDM/titleType",
          "decode": "Official Study Title"
        },
        "instanceType": "StudyTitle"
      },
      {
        "id": "title_2",
        "text": "ZUMA-7",
        "type": {
          "code": "StudyAcronym",
          "codeSystem": "http://www.cdisc.org/USDM/titleType",
          "decode": "Study Acronym"
        },
        "instanceType": "StudyTitle"
      }
    ],
    "identifiers": [
      {
        "id": "sid_1",
        "text": "KTE-C19-107",
        "identifierType": "SponsorProtocolNumber",
        "issuingOrganization": "Kite Pharma, Inc.",
        "instanceType": "StudyIdentifier"
      },
      {
        "id": "sid_2",
        "text": "016278",
        "identifierType": "IND",
        "issuingOrganization": "FDA",
        "instanceType": "StudyIdentifier"
      },
      {
        "id": "sid_3",
        "text": "2017-002261-22",
        "identifierType": "EudraCT",
        "issuingOrganization": "EudraCT",
        "instanceType": "StudyIdentifier"
      },
      {
        "id": "sid_4",
        "text": "KTE-C19",
        "identifierType": "InternalStudyID",
        "issuingOrganization": "Kite Pharma, Inc.",
        "instanceType": "StudyIdentifier"
      }
    ],
    "organizations": [
      {
        "id": "org_1",
        "name": "Kite Pharma, Inc.",
        "type": {
          "code": "Sponsor",
          "codeSystem": "http://www.cdisc.org/USDM/organizationType",
          "decode": "Sponsor"
        },
        "role": "Sponsor",
        "instanceType": "Organization"
      },
      {
        "id": "org_2",
        "name": "Gilead Sciences Inc.",
        "type": {
          "code": "Sponsor",
          "codeSystem": "http://www.cdisc.org/USDM/organizationType",
          "decode": "Sponsor"
        },
        "role": "Parent Company",
        "instanceType": "Organization"
      },
      {
        "id": "org_3",
        "name": "Data Safety Monitoring Board",
        "type": {
          "code": "RegulatoryAuthority",
          "codeSystem": "http://www.cdisc.org/USDM/organizationType",
          "decode": "Regulatory Authority"
        },
        "role": "Safety Oversight",
        "instanceType": "Organization"
      }
    ],
    "studyPhase": {
      "code": "Phase3",
      "codeSystem": "http://www.cdisc.org/USDM/studyPhase",
      "decode": "Phase 3"
    },
    "studyType": "Interventional",
    "indication": {
      "id": "ind_1",
      "name": "Relapsed/Refractory Diffuse Large B Cell Lymphoma",
      "description": "Adult subjects with relapsed/refractory diffuse large B-cell lymphoma (r/r DLBCL) after first-line rituximab and anthracycline-based chemotherapy.",
      "instanceType": "Indication"
    }
  }
}